282 related articles for article (PubMed ID: 31597402)
1. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.
Rosas Plaza X; van Agthoven T; Meijer C; van Vugt MATM; de Jong S; Gietema JA; Looijenga LHJ
Cells; 2019 Oct; 8(10):. PubMed ID: 31597402
[TBL] [Abstract][Full Text] [Related]
2. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
van Agthoven T; Eijkenboom WMH; Looijenga LHJ
Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337
[TBL] [Abstract][Full Text] [Related]
3. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
4. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
5. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
6. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
8. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
[TBL] [Abstract][Full Text] [Related]
9. The present and future of serum diagnostic tests for testicular germ cell tumours.
Murray MJ; Huddart RA; Coleman N
Nat Rev Urol; 2016 Dec; 13(12):715-725. PubMed ID: 27754472
[TBL] [Abstract][Full Text] [Related]
10. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
11. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
13. Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors?
Spiekermann M; Dieckmann KP; Balks T; Bullerdiek J; Belge G
Anticancer Res; 2015 Jan; 35(1):117-21. PubMed ID: 25550541
[TBL] [Abstract][Full Text] [Related]
14. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
Murray MJ; Bell E; Raby KL; Rijlaarsdam MA; Gillis AJ; Looijenga LH; Brown H; Destenaves B; Nicholson JC; Coleman N
Br J Cancer; 2016 Jan; 114(2):151-62. PubMed ID: 26671749
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
16. Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study.
Myklebust MP; Thor A; Rosenlund B; Gjengstø P; Karlsdottir Á; Brydøy M; Bercea BS; Olsen C; Johnson I; Berg MI; Langberg CW; Andreassen KE; Kjellman A; Haugnes HS; Dahl O
Sci Rep; 2021 Aug; 11(1):15582. PubMed ID: 34341387
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid.
Dieckmann KP; Spiekermann M; Balks T; Ikogho R; Anheuser P; Wosniok W; Loening T; Bullerdiek J; Belge G
Urol Int; 2016; 97(1):76-83. PubMed ID: 26989896
[TBL] [Abstract][Full Text] [Related]
18. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer.
Lobo J; Leão R; Gillis AJM; van den Berg A; Anson-Cartwright L; Atenafu EG; Kuhathaas K; Chung P; Hansen A; Bedard PL; Jewett MAS; Warde P; O'Malley M; Sweet J; Looijenga LHJ; Hamilton RJ
Eur Urol Oncol; 2021 Jun; 4(3):483-491. PubMed ID: 33288479
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
20. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
